Baxter (BAX) Q4 2024 Earnings Call Transcript

BAX is transitioning from a “fix-and-separate” story into a cleaner operating-leverage story, and that changes the stock’s setup. The key second-order effect is that the post-Vantive capital structure plus TSA income gives management a temporary margin cushion while stranded-cost removal creates an earnings glidepath that can outpace revenue growth for several quarters. That makes 2025 less about top-line perfection and more about whether execution discipline can turn a mid-single-digit sales profile into high-single-digit EPS growth.

The most underappreciated positive is the competitive durability of the North Cove recovery. Customers that would normally multi-source during a disruption appear to have largely stayed put, which reduces the risk that the hurricane permanently resets share in saline/IV solutions. If that holds through the next two quarters, the market may have overestimated the lasting share loss and underestimated the pricing power embedded in Baxter’s installed base and GPO footprint.

The main bearish risk is that the current guidance embeds several “temporary supports” that fade: TSA income, favorable mix from launch ramps, and working-capital normalization after Q1. If product launches slip or FLC/CCS recovery proves slower, the margin bridge becomes much less impressive once the hurricane comps roll off. The CEO search is a real wildcard too: a strategic reset could improve the long-term multiple, but near-term it also raises the probability of pause on buybacks/capital deployment until the new leader re-underwrites the portfolio.

Consensus is probably still too anchored to Baxter as a low-growth, event-driven healthcare name. The more interesting read is that the company’s operational reset is creating a path to a higher-quality earnings base, and the market may be slow to re-rate that until it sees one more quarter of uninterrupted recovery plus proof that free cash flow snaps back after the Q1 working-capital dip.